The lancet oncology
-
The lancet oncology · Oct 2018
Randomized Controlled Trial Multicenter Study Comparative StudyOverall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival. ⋯ Array BioPharma, Novartis.
-
The lancet oncology · Oct 2018
Maternal use of hormonal contraception and risk of childhood leukaemia: a nationwide, population-based cohort study.
Maternal hormonal contraception has been suspected of being linked to an increased risk of childhood cancer. The aim of this study was to assess the association between maternal use of hormonal contraception and diagnosis of leukaemia in their children. ⋯ The Danish Cancer Research Foundation, the Arvid Nilssons Foundation, the Gangsted Foundation, the Harboe Foundation, and the Johannes Clemmesens Foundation.